{
  "slug": "exin-therapeutics",
  "name": "Exin Therapeutics",
  "yc_id": 29986,
  "batch": "Winter 2025",
  "website": "https://www.exintherapeutics.com/",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:33:59.475778",
    "website": "https://www.exintherapeutics.com/",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 2679.42,
      "final_url": "https://www.exintherapeutics.com/",
      "redirected": false,
      "checked_at": "2025-10-17T01:34:02.155205"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "exintherapeutics.com",
      "registrar": "IONOS SE",
      "creation_date": "2024-11-01T16:16:33",
      "expiration_date": "2025-11-01T16:16:33",
      "domain_age_days": 349,
      "domain_age_years": 1.0,
      "name_servers": [
        "NS1023.UI-DNS.ORG",
        "NS1087.UI-DNS.DE",
        "NS1102.UI-DNS.COM",
        "NS1117.UI-DNS.BIZ"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": true,
      "x_frame_options": true,
      "x_content_type_options": true,
      "x_xss_protection": true,
      "referrer_policy": true,
      "security_score": 83,
      "server": "ESF"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:42:12.783939",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:52:15.623265",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "AI-driven drug discovery acceleration",
        "Precision medicine for neurological disorders",
        "Increasing prevalence of autism and neurodegenerative diseases"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary high-density multimodal mouse data and AI models trained on in-house generated datasets",
      "differentiation": "Focus on neural activity modification using AI-guided high-throughput mouse studies for neurotherapeutics",
      "competitive_advantages": [
        "Oxford-trained team with deep neuroscience expertise",
        "In-house data generation capability",
        "Experienced advisory board from Harvard and Science Corp"
      ],
      "competitive_vulnerabilities": [
        "Small team size limiting execution capacity",
        "Dependence on mouse model translational validity"
      ]
    },
    "business_model": {
      "revenue_model": "Biotech licensing and partnerships",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "pre-seed",
      "growth_indicators": [
        "Recent Y Combinator acceptance",
        "Strong academic pedigree",
        "Clear therapeutic focus areas"
      ],
      "growth_bottlenecks": [
        "Long drug development timelines",
        "Need for significant capital raises",
        "Regulatory approval requirements"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Clinical trial failure risk",
        "AI model validation challenges",
        "Competition from Big Pharma AI initiatives"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Large addressable market in neurotherapeutics",
        "Strong technical team with relevant expertise",
        "AI-first approach to drug discovery"
      ],
      "concerns": [
        "Early stage with unproven technology",
        "High capital requirements for drug development",
        "Long path to revenue generation"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Recursion Pharmaceuticals",
        "Insitro",
        "Atomwise"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Validate AI models with initial proof-of-concept studies",
        "Secure Series A funding for expanded R&D"
      ],
      "expansion_opportunities": [
        "Partnership with academic medical centers",
        "Expansion to additional neurological indications beyond epilepsy and Parkinson's"
      ]
    },
    "tokens_used": {
      "input": 742,
      "output": 610,
      "total": 1352,
      "estimated_cost": 0.011376
    },
    "status": "success"
  },
  "phase8_complete": true
}